Hostname: page-component-7479d7b7d-q6k6v Total loading time: 0 Render date: 2024-07-11T15:26:32.999Z Has data issue: false hasContentIssue false

Treatment of cycloserine induced psychosis - a case series

Published online by Cambridge University Press:  16 April 2020

S. Bangar*
Affiliation:
General Psychiatry, Driffield CMHT, Driffield, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Cycloserine is a highly effective second line anti-tuberculosis medication, the use of which has increased in recent times due to emergence of multi-drug resistance. One of the side-effects is psychosis characterized by paranoia, hallucinations and affective instability. These symptoms are usually reported within the first 2 weeks of therapy in 30–50% of patients receiving Cycloserine 500 mg. At a dose of 100mg and above it leads to a hyperdopaminergic state which in turn could lead to psychosis. However, as this is a very effective treatment in people with multi-drug resistant tuberculosis, it is not always possible to omit treatment due to remergence of life threatening illness. We present findings from few patients on this medication who were referred to us for management of psychotic symptoms.

Aims and objectives

To treat the psychotic symptoms with anti-psychotic which would enable patient to continue Cycloserine. Also to monitor the response to an anti-psychotic.

Methods

Data was collected from the patient’s case notes, full psychiatric assessment and interviewing the relative. Patient was followed up in the out-patient clinic to monitor response to anti-psychotic medication.

Results

Patients were treated with both typical and atypical medication with good response and it was possible to continue with Cycloserine in one case.

Conclusion

Cycloserine induced psychosis can mimic any other psychotic illness and can be effectively treated with anti-psychotics.

Type
P03-58
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.